Liver fibrosis in chronic hepatitis C: view of the problem in era of interferon-free treatment


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The article describes the current understanding of the pathogenesis of liver fibrosis in chronic hepatitis C, and the mechanisms of regression of fibrosis against the background of antiviral therapy. Many years of experience of use of interferon-containing schemes for the treatment of chronic hepatitis C suggests a possibility of reverse development of fibrosis after achieving a sustained virologic response, while the reversibility of fibrosis against the background of antiviral therapy using drugs with direct antiviral action requires further evaluation. Clinical observations confirming positive influence of drugs with direct antiviral action on the regression of liver fibrosis in patients with liver cirrhosis of HCV-etiology are presented.

Full Text

Restricted Access

About the authors

I. G Bakulin

FSBEI HE North-Western State Medical University n.a. I.I. Mechnikov of RMH

E. V Vinnitskaya

SBHCI Moscow Clinical Research Center of Moscow Healthcare Department

A. V Polukhina

SBHCI Moscow Clinical Research Center of Moscow Healthcare Department

Email: a.polukhina@mknc.ru

Yu. G Sandler

SBHCI Moscow Clinical Research Center of Moscow Healthcare Department

References

  1. Guidelines for the screening, care and treatment of persons with hepatitis c infection. WHO, 2014.
  2. Бакулин И.Г. Актуальные вопросы противовирусной терапии хронических гепатитов В и С. Эксперим. и клин. гастроэнтерол. 2010; 5:3-9.
  3. Ющук Н.Д., Знойко О.О., Дудина К.Р., Зайратьянц О.В., Якушечкина Н.А. Проблемы учета заболеваемости и смертности от хронического гепатита С в Российской федерации. Здравоохранение. 2012;12:68-76.
  4. Курышева М.А. Фиброз печени: прошлое, настоящее и будущее. РМЖ. 2010;18(28):1713-16.
  5. Некрасова Т.П. Морфологическое исследование в оценке степени фиброза печени при хронических вирусных гепатитах. Гепатологический форум. 2007;2:11-3.
  6. Parsons C.J., Takashima M., Rippe R.A. Molecular mechanisms of hepatic fibrogenesis. J. Gastroenterol. Hepatol. 2007;22(1):79-84.
  7. Yin C., Evason K.J., Asahina K., Stainier D.Y.R. Hepatic stellate cells in liver development, regeneration, and cancer. J. Clin. Invest. 2013;123(5):1902-10.
  8. Dranoff J.A., Wells R.G. Portal fibroblasts: Underappreciated mediators of biliary fibrosis. Hepatology 2010;51(4):1438-44.
  9. Luo Y., Xiang H.-L., Tang F., Tun H. Role of bone marrow stem cells in hepatic fibrosis. World Chinese J. Digestol. 2008;16(14):1543-47.
  10. Heymann F., Trautwein C., Tacke F. Monocytes and macrophages as cellular targets in liver fibrosis. Inflamm. Allergy Drug Targets. 2009;8(4):307-18.
  11. Leifeld L. Early upregulation of chemokine expression in fulminant hepatic failure. J. Pathol. 2003;199:335-44.
  12. Panasiuk А. Platelet and monocyte activations and relation to stages of liver cirrhosis. World J. Gastroenterol. 2005;11(18):2754-58.
  13. Deshmane S.L., Kremlev S., Amini S., Sawaya B.E. Monocyte Chemoattractant Protein-1 (MCP-1): An Overview. J. Interferon. Cytokine Res. 2009;29(6):3313-26.
  14. Shantsila Е., Lip G.Y.H. Monocyte-Endothelium and Monocyte-Myocardial Interactions. Arterioscler. Thromb. Vasc. Biol. 2009;29:1433-38.
  15. Wynn А. Cellular and molecular mechanisms of fibrosis. J. Pathol. 2008;21:199-210.
  16. Kim J.H., bee C.H., Lee S.W. Hepatitis C virus infection stimulates transforming growth factor-ß1 expression through up-regulating miR-192. J. Microbiol. 2016;54(7):520-26.
  17. Tache D., Bogdan F., Pisoschi C., Baniţă M., Stănciulescu C., Fusaru A.M., Comănescu V. Evidence for the involvement of TGF-ß1-CTGF axis in liver fibrogenesis secondary to hepatic viral infection. Rom. J. Morphol. Embryol. 2011;52(Suppl. 1):409-12.
  18. Шульпекова Ю.О., Ивашкин В.Т., Мамаев С.Н. Уровень трансформирующего фактора роста-1b (TGF-1b) в сыворотке крови и показатели клеточного иммунитета у больных хроническим гепатитом С. Рос. журн. гастроэнтерол., гепатол., колопроктол. 2003;11(1):14.
  19. Campbell J.S., Hughes S.D., Gilbertson D.G., Palmer T.E., Holdren M.S., Haran A.C., Odell M.M., Bauer R.L., Ren H.P., Haugen H.S., Yeh M.M., Fausto N. Platelet-derived growth factor C induces liver fibrosis, steatosis, and hepatocellular carcinoma. Proc. Natl. Acad. Sci. USA. 2005;102(9):3389-94
  20. Корой П.В., Ягода А.В. Тромбоциты как индикаторы печеночного фиброгенеза. Медицинский вестник Северного Кавказа. 2007;3(7):55-63.
  21. Yang L., Kwon J., Popov Y., Gajdos G.B., Ordog T., Brekken R.A., Mukhopadhyay D., Schuppan D., Bi Y., Simonetto D., Shah V.H. Vascular endothelial growth factor promotes fibrosis resolution and repair in mice. Gastroenterology. 2014;146(5):1339-50.
  22. Taura K., Iwaisako K., Hatano E., Uemoto S. Controversies over the Epithelial-to-Mesenchymal Transition in Liver Fibrosis. J. Clin. Med. 2016;5:9.
  23. Scholten D., Osterreicher C.H., Scholten A., Iwaisako K., Gu G., Brenner D.A., Kisseleva T. Genetic labeling does not detect epithelial-to-mesenchymal transition of cholangiocytes in liver fibrosis in mice. Gastroenterology. 2010;139(3):987-98.
  24. Nagase H., Woessner J. Matrix Metalloproteinases. J. Biol. Chem. 1999;274(31):21491-94.
  25. Bode W., Fernandez-Catalan С., Tschesche H. Structural properties of matrix metalloproteinases. Cell. Mol. Life Sci. 1999;55:639-52.
  26. Troeberg L., Nagase H. Analysis of TIMP expression and activity. Methods Mol. Med. 2007;135:251-67.
  27. Винницкая Е.В., Юнусова Ю.М. Фиброз печени: возможности обратного развития. Фарматека. 2012;13:11-3.
  28. Павлов Ч.С., Ивашкин В.Т. Биопсия печени: методология и практика сегодня. Рос. журн. гастроэнтерол, гепатол., колопроктол. 2006;16(4):65-78.
  29. Глушенков Д.В., Коновалова О.Н., Ивашкин В.Т. Неинвазивная диагностика фиброза печени на ранних стадиях его развития. Рос. журн. гастроэнтерол., гепатол., колопроктол. 2008;18(5):83.
  30. Павлов Ч.С., Глушенков Д.В., Ивашкин В.Т. Современные возможности эластометрии, фибро- и актитеста в диагностике фиброза печени. Рос. журн. гастроэнтерол., гепатол.и колопроктол. 2008;18(4):43-52.
  31. Шептулина А.Ф., Широкова Е.Н., Ивашкин В.Т. Неинвазивная диагностика фиброза печени: роль сывороточных маркёров. Рос. журн. гастроэнтерол., гепатол. и колопроктол. 2015;25(2):28-40.
  32. Koretz R. Hepatitis C treatment: no benefits and possible harm. http://www.news-medical.net/ health/Hepatitis-C-treatment-no-benefits-and-possible-harm.aspx
  33. George S.L., Bacon B.R., Brunt E.M., Mihindukulasuriya K.L., Hoffmann J., Di Bisceglie A.M. Clinical, virologie, histologic, and biochemical outcomes after successful HCV therapy: A 5-year follow-up of 150 patients. Hepatology. 2009;49:729-38.
  34. D'Ambrosio R., Aghemo A., Rumi M., Ronchi G., Donato M.F., Paradis V., Colombo M., Bedossa P. A morphometric and immunohistochemical study to assess the benefit of a sustained virological response in hepatitis C virus patients with cirrhosis. Hepatology. 2012; 56:532-43.
  35. Di Bisceglie A.M., Shiffman M.L., Everson G.T., Lindsay K.L., Everhart J.E., Wright E.C., bee W.M., Lok A.S., Bonkovsky H.L., Morgan T.R., Ghany M.G., Morishima C., Snow K.K., Dienstag J.L.; HALT-C Trial Investigators. Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N. Engl. J. Med. 2008;359:2429-41.
  36. Di Bisceglie A.M., Stoddard A.M., Dienstag J.L., Shiffman M.L., Seeff L.B., Bonkovsky H.L., Morishima C., Wright E.C., Snow K.K., Lee W.M., Fontana R.J., Morgan T.R., Ghany M.G.; HALT-C Trial Group. Excess mortality in patients with advanced chronic hepatitis C treated with long-term peginterferon. Hepatology. 2011;53:1100-108.
  37. van der Meer A.J., Wedemeyer H., Feld J.J., Hansen B.E., Manns M.P., Zeuzem S., Janssen H.L. Is there sufficient evidence to recommend antiviral therapy in hepatitis C? J. Hepatol. 2014;60(1):191-96.
  38. Hsu C.S., Huang C.J., Kao J.H., Lin H.H., Chao Y.C., Fan Y.C., Tsai P.S. Interferon-based therapy decreases risks of hepatocellular carcinoma and complications of cirrhosis in chronic hepatitis C patients. PLoS One. 2013;8(7):70458.
  39. Labarga P., Fernandez-Montero J.V., de Mendoza C., Barreiro P., Pinilla J., Soriano V. Liver fibrosis progression despite HCV cure with antiviral therapy in HIV-HCV-coinfected patients. Antivir. Ther. 2015;20(3):329-34.
  40. Vukobrat-Bijedic Z., Husic-Selimovic A. Analysis of effect of antiviral therapy on regression of liver fibrosis in patients with HCV infection. Mater. Sociomed. 2014;26(3):173-76.
  41. Bakulin I., Pacechnikov V., Varlamicheva A., Sanina I. NS3-protease inhibitors for treatment of chronic hepatitis C: efficacy and safety. World J. Hepatol. 2014;6(5):326-39.
  42. Абдурахманов Д.Т., Морозов В.Г., Никитин И.Г и др. Безопасность и эффективность телапревира в лечении хронического гепатита с у больных российской популяции, включенных в исследование по программе раннего доступа. Рос. журн. гастроэнтерол., гепатол., колопроктол. 2014;23(1):39-46.
  43. Crissien A.M., et al. Regression of advanced fibrosis or cirrhosis measured by elastography in patients with chronic hepatitis C who achieve sustained virologic response after treatment for HCV. AASLD Liver Meeting. 2015: аbstract. 108.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2016 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies